BSB-1001 for Blood Cancers
Trial Summary
The trial information does not specify if you need to stop taking your current medications. However, it mentions that you cannot have had certain treatments like CAR-T therapy within 2 years or investigational agents recently, so it's best to discuss your specific medications with the trial team.
Research on similar treatments, like BH3-mimetics, shows they can effectively target and kill cancer cells in blood cancers by overcoming blocks in apoptosis (a process of programmed cell death). This suggests that BSB-1001, if it works similarly, might also be effective in treating blood cancers.
168911BSB-1001 is unique because it may act as a BH3 mimetic, similar to the small-molecule S1, which inhibits multiple anti-apoptotic proteins like Bcl-2, Mcl-1, and Bcl-XL that are often overexpressed in blood cancers. This multi-targeted approach could potentially make it more effective in inducing cancer cell death compared to treatments that target only one of these proteins.
3581314Dasatinib, which may be related to BSB-1001, has been studied for safety in various blood cancers. In a study with patients having acute lymphoblastic leukemia, dasatinib was generally well-tolerated, with most side effects being mild and manageable. Another study in myelodysplastic syndrome patients also found dasatinib to be safe, though its effectiveness was limited.
2471012Eligibility Criteria
This trial is for patients with blood cancers like AML, ALL, or MDS who are getting a stem cell transplant from a donor that matches their tissue type. Participants should not have had previous treatments that would interfere with the study.Inclusion Criteria
Exclusion Criteria